Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PNH With Extravascular Hemolysis Approves Factor D Inhibitor.

2.

Study Finds Microplastics Near Tumors; Experts Doubt Results

3.

Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer

4.

Research indicates that combining AI models enhances the ability to predict breast cancer risk.

5.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot